-
Je něco špatně v tomto záznamu ?
Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke
P. Sulzgruber, S. Wassmann, AG. Semb, W. Doehner, P. Widimsky, T. Gremmel, JC. Kaski, G. Savarese, GMC. Rosano, C. Borghi, K. Kjeldsen, C. Torp-Pedersen, TA. Schmidt, BS. Lewis, H. Drexel, J. Tamargo, D. Atar, S. Agewall, A. Niessner,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, směrnice pro lékařskou praxi, práce podpořená grantem, přehledy
NLK
PubMed Central
od 2015
ProQuest Central
od 2016-10-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2016-10-01 do Před 1 rokem
Oxford Journals Open Access Collection
od 2015-01-01
PubMed
31119266
DOI
10.1093/ehjcvp/pvz016
Knihovny.cz E-zdroje
- MeSH
- antikoagulancia aplikace a dávkování škodlivé účinky MeSH
- aplikace orální MeSH
- cévní mozková příhoda diagnóza epidemiologie prevence a kontrola MeSH
- fibrilace síní diagnóza farmakoterapie epidemiologie MeSH
- hodnocení rizik MeSH
- klinické rozhodování MeSH
- konsensus MeSH
- krvácení chemicky indukované MeSH
- lidé MeSH
- metody pro podporu rozhodování MeSH
- rizikové faktory MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- směrnice pro lékařskou praxi MeSH
Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20023843
- 003
- CZ-PrNML
- 005
- 20201214131411.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/ehjcvp/pvz016 $2 doi
- 035 __
- $a (PubMed)31119266
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Sulzgruber, Patrick $u Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
- 245 10
- $a Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke / $c P. Sulzgruber, S. Wassmann, AG. Semb, W. Doehner, P. Widimsky, T. Gremmel, JC. Kaski, G. Savarese, GMC. Rosano, C. Borghi, K. Kjeldsen, C. Torp-Pedersen, TA. Schmidt, BS. Lewis, H. Drexel, J. Tamargo, D. Atar, S. Agewall, A. Niessner,
- 520 9_
- $a Oral anticoagulation in patients presenting with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 (CHA2DS2-VASc of 2 in women) remains a challenging approach in clinical practice. Therapeutic decisions need to balance the individual benefit of reducing thromboembolic risk against the potential harm due to an increase in bleeding risk in this intermediate risk patient population. Within the current opinion statement of the European Society of Cardiology working group of cardiovascular pharmacotherapy and the European Society of Cardiology council on stroke the currently available evidence on the anti-thrombotic management in patients presenting with a CHA2DS2-VASc of 1 is summarized. Easily applicable tools for a personalized refinement of the individual thromboembolic risk in patients with atrial fibrillation and a CHA2DS2-VASc score of 1 that guide clinicians through the question whether to anticoagulate or not are provided.
- 650 _2
- $a aplikace orální $7 D000284
- 650 _2
- $a antikoagulancia $x aplikace a dávkování $x škodlivé účinky $7 D000925
- 650 _2
- $a fibrilace síní $x diagnóza $x farmakoterapie $x epidemiologie $7 D001281
- 650 _2
- $a klinické rozhodování $7 D000066491
- 650 _2
- $a konsensus $7 D032921
- 650 _2
- $a metody pro podporu rozhodování $7 D003661
- 650 _2
- $a krvácení $x chemicky indukované $7 D006470
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a cévní mozková příhoda $x diagnóza $x epidemiologie $x prevence a kontrola $7 D020521
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Wassmann, Sven $u Cardiology Pasing, Institutstraße 14, 81241 Munich, Germany. University of the Saarland, Kirrberger Straße 100, 66424 Homburg, Saar, Germany.
- 700 1_
- $a Semb, Anne Grete $u Department of Rheumatology, Preventive Cardio-Rheuma Clinic, Diakonhjemmet Hospital, Diakonveien 12, 0370 Oslo, Norway.
- 700 1_
- $a Doehner, Wolfram $u Department of Cardiology (Virchow Klinikum), German Centre for Cardiovascular Research (DZHK), Oudenarder Straße 16, 13316 Berlin, Germany. BIH Center for Regenerative Therapies (BCRT), Charité Universitaetsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
- 700 1_
- $a Widimsky, Petr $u Cardiocenter, Third Faculty of Medicine, Charles University, Opletalova 38, 110 00 Staré Město, Prague, Czech Republic.
- 700 1_
- $a Gremmel, Thomas $u Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. Department of Internal Medicine, Cardiology and Nephrology, Landesklinikum Wiener Neustadt, Corvinusring 3-5, 2700 Wiener Neustadt, Austria.
- 700 1_
- $a Kaski, Juan Carlos $u Molecular and Clinical Sciences Research Institute, St George's, University of London, Cranmer Terrace, Tooting, London SW17 0RE, UK.
- 700 1_
- $a Savarese, Gianluigi $u Cardiology Division, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Eugeniavägen 3, 171 76 Solna, Stockholm, Sweden.
- 700 1_
- $a Rosano, Giuseppe M C $u IRCCS San Raffaele Roma, Via della Pisana, 235, 00163 Roma, Italy. St George's Hospitals NHS Trust, University of London, Cranmer Terrace, Tooting, London SW17 0RE, UK.
- 700 1_
- $a Borghi, Claudio $u Atherosclerosis Research Unit, Medical and Surgical Sciences Department, Sant'Orsola-Malpighi Hospital, University of Bologna, Via Zamboni, 33, 40126 Comune di Bologna BO, Italy.
- 700 1_
- $a Kjeldsen, Keld $u Department of Cardiology, Copenhagen University Hospital (Hvidovre-Amager), Blegdamsvej 9, 2100 Copenhagen, Denmark. Department of Health Science and Technology, The Faculty of Medicine, Aalborg University, Fredrik Bajers Vej 5, 9100 Aalborg, Denmark.
- 700 1_
- $a Torp-Pedersen, Christian $u Department of Health Sciences and Technology, Aalborg University, Fredrik Bajers Vej 5, 9100 Aalborg, Denmark. Department of Cardiology, Aalborg University Hospital, Fredrik Bajers Vej 5, 9100 Aalborg, Denmark.
- 700 1_
- $a Schmidt, Thomas Andersen $u Emergency Department, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Bispebjerg Bakke 23, 2400 Copenhagen, Denmark.
- 700 1_
- $a Lewis, Basil S $u Lady Davis Carmel Medical Center, Mikhal St 7, 3436212 Haifa, Israel. Technion-Israel Institute of Technology, Ruth and Bruce Rappaport School of Medicine, Efron St 1, 3436212 Haifa, Israel.
- 700 1_
- $a Drexel, Heinz $u VIVIT Research, Landeskrankenhaus Feldkirch, Carinagasse 47, 6800 Feldkirch, Austria. Private University of the Principality of Liechtenstein, Dorfstrasse 24. FL-9495 Triesen, Principality of Liechtenstein.
- 700 1_
- $a Tamargo, Juan $u Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense, Avda. de Séneca, 2 Ciudad Universitaria, 28040 Madrid, Spain.
- 700 1_
- $a Atar, Dan $u Department of Cardiology, Oslo University Hospital and Institute of Clinical Medicine, Oslo University, Klaus Torgírds vei 3, 0372 Oslo, Norway.
- 700 1_
- $a Agewall, Stefan $u Department of Cardiology, Oslo University Hospital and Institute of Clinical Medicine, Oslo University, Klaus Torgírds vei 3, 0372 Oslo, Norway.
- 700 1_
- $a Niessner, Alexander $u Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
- 773 0_
- $w MED00195025 $t European heart journal. Cardiovascular pharmacotherapy $x 2055-6845 $g Roč. 5, č. 3 (2019), s. 171-180
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31119266 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201214131409 $b ABA008
- 999 __
- $a ok $b bmc $g 1596162 $s 1114519
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 5 $c 3 $d 171-180 $e 20190701 $i 2055-6845 $m European heart journal. Cardiovascular pharmacotherapy $n Eur Heart J Cardiovasc Pharmacother $x MED00195025
- LZP __
- $a Pubmed-20201125
